Tapentadol prolonged release (Palexia® SR) is recommended as an option for restricted use within NHS Wales, only in the following subpopulation within its licensed indication: Patients with severe chronic pain, in whom morphine sulfate modified release has failed to provide adequate pain control or is not tolerated. Tapentadol prolonged release (Palexia® SR) is not recommended for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics, outside of the subpopulation described above.